COPPELL, Texas — AstraZeneca has unveiled its newly expanded, state-of-the-art manufacturing facility in Coppell, Texas, following a $445 million investment that will double the production capacity of Lokelma for patients in the United States and globally.
The Coppell expansion comes shortly after the groundbreaking of AstraZeneca’s new manufacturing facility in Albemarle County, Virginia, and forms part of the company’s broader $50 billion investment in U.S. research, development, and manufacturing over the next five years, announced in July 2025.
“Our manufacturing facility in Coppell serves as both a critical pillar in global healthcare and has played an important role in supporting the local workforce over the past 10 years,” said Jim Fox, Senior Vice President, Americas Supply Operations at AstraZeneca. “The expansion underscores our commitment to patients and support for Texas’ long-term vision for scientific growth and innovation.”
The Coppell facility, which employs more than 250 people, serves as the sole global manufacturing site for Lokelma, supplying the medicine to over 50 countries. The expansion adds a new 9,000-square-foot building housing two novel manufacturing lines, along with upgrades to laboratory testing areas, warehousing, utilities, and administrative spaces to further strengthen production and quality capabilities.
As part of the unveiling event, AstraZeneca’s STEM education partner, Learning Undefeated, showcased its interactive mobile lab, Breakout Box: Manufacturing Mission. The mobile lab aims to inspire the next generation of STEM leaders by offering hands-on experiences in high-demand manufacturing fields such as robotics, welding, and data analytics. It will be available to schools across Texas to promote interest in advanced manufacturing careers.
